Adherence as a particular issue with protease inhibitors
Journal of the Association of Nurses in AIDS CarePublished 1 January 1997
David Katzenstein
Citations37
SJR quartileQ1
SJR score0.57
SNIP0.54
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
It is imperative, then, that patients and clinicians alike are fully educated about the importance of patients taking all the pills in these new, admittedly complex, antiretroviral regimens.
Abstract
Suboptimal therapeutic doses of HIV protease inhibitors lead to the emergence of drug resistance and reduced drug efficacy. It is imperative, then, that patients and clinicians alike are fully educated about the importance of patients taking all the pills in these new, admittedly complex, antiretroviral regimens. With protease inhibitors especially, missing doses and/or taking drug holidays or partial doses will mean the rapid emergence of HIV isolates that are resistant to these drugs.
Keywords
Immunology and MicrobiologyMedicine
ScienceHIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time
3,550 Citations1996Alan S. Perelson, Avidan U. Neumann +3 more
A new mathematical model was used to analyze a detailed set of human immunodeficiency virus-type 1 (HIV-1) viral load data collected from five infected individuals after the administration of a potent inhibitor of HIV-1 protease, providing not only a kinetic picture ofAIDS pathogenesis, but also theoretical principles to guide the development of treatment strategies.
SciencePrognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma
2,705 Citations1996John W. Mellors, Charles R. Rinaldo +4 more
Plasma viral load was a better predictor of progression to AIDS and death than was the number of CD4+ T cells, and the risk of acquired immunodeficiency syndrome (AIDS) and death in study subjects was directly related to plasma viral load at study entry.
ScienceHIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy
1,985 Citations1995John M. Coffin
Results lead to a simple steady-state model in which infection, cell death, and cell replacement are in balance, and imply that the unique feature of HIV is the extraordinarily large number of replication cycles that occur during infection of a single individual.
NatureIn vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
979 Citations1995Jon H. Condra, William A. Schleif +14 more
Five resistant variants isolated from patients undergoing therapy with the protease inhibitor MK-639 exhibited cross-resistance to all members of a panel of six structurally diverse protease inhibitors, suggesting that com-bination therapy with multiple protease inhibition may not prevent loss of antiviral activity resulting from resistance selection.
New England Journal of MedicineTreatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter
536 Citations1995Joseph J. Eron, Sharon L. Benoit +7 more
In HIV-infected patients with little or no prior antiretroviral therapy, treatment with a combination of lamivudine and zidovudine is well tolerated over a one-year period and produces more improvement in immunologic and virologic measures than does treatment with either agent alone.
New England Journal of MedicineThe Relation of Virologic and Immunologic Markers to Clinical Outcomes after Nucleoside Therapy in HIV-Infected Adults with 200 to 500 CD4 Cells per Cubic Millimeter
485 Citations1996David Katzenstein, Scott M. Hammer +10 more
Both the risk of the progression of HIV disease and the efficacy of antiretroviral therapy are strongly associated with the plasma level of HIV RNA and with the viral phenotype.
JAMAPatient Compliance and Drug Failure in Protease Inhibitor Monotherapy
193 Citations1996Geertrui F. Vanhove
The Journal of Infectious DiseasesVirologic and Immunologic Benefits of Initial Combination Therapy with Zidovudine and Zalcitabine or Didanosine Compared with Zidovudine Monotherapy
94 Citations1996Robert T. Schooley, C H Ramírez-Ronda +15 more
Although this trial was not designed as a clinical end-point study, patients assigned to zidovudine plus didanosine combination therapy experienced a significant delay in time to first AIDS-defining event or death compared with those assigned toZidovUDine monotherapy.
JAMAUpdate: Mortality Attributable to HIV Infection Among Persons Aged 25-44 Years— United States, 1994
66 Citations1996
This report updates national trends in deaths caused by HIV infection in 1994, which continue to increase.
The Journal of Infectious DiseasesHuman Immunodeficiency Virus Reverse Transcriptase Codon 215 Mutations Diminish Virologic Response to Didanosine-Zidovudine Therapy in Subjects with Non-Syncytium-Inducing Phenotype
22 Citations1996Mark Holodniy, David Katzenstein +3 more